William R Hiatt
Affiliation: University of Colorado Denver
- A validated biomarker panel to identify peripheral artery diseaseWilliam R Hiatt
University of Colorado School of Medicine, Division of Cardiology, Aurora, CO 80045, USA
Vasc Med 17:386-93. 2012..The model also performed well in subjects with no prior history of PAD. Thus, a biomarker panel may have a role for identifying PAD...
- Effect of propionyl-L-carnitine on a background of monitored exercise in patients with claudication secondary to peripheral artery diseaseWilliam R Hiatt
University of Colorado School of Medicine, Division of Cardiology and CPC Clinical Research, Aurora, Colorado 80045, USA
J Cardiopulm Rehabil Prev 31:125-32. 2011..This trial tested the hypothesis that propionyl-L-carnitine (PLC), in combination with monitored home-based exercise training, would improve treadmill peak walking time (PWT) over exercise training alone...
- The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) ProgramJudith G Regensteiner
Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA
Vasc Med 13:15-24. 2008....
- Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise trainingW Schuyler Jones
Division of Cardiology, Duke University Medical Center, Durham, NC, USA
Vasc Med 17:94-100. 2012..These somewhat unexpected findings suggest that further investigation into the mechanism of vascular responses to exercise training in PAD patients is warranted...
- Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patientsBrian D Duscha
Duke University Medical Center, Division of Cardiology, Durham, NC 27710, USA
Arterioscler Thromb Vasc Biol 31:2742-8. 2011..This study tested the hypothesis that in PAD patients who undergo supervised exercise training, increases in capillary density (CD) in calf muscle take place before improvements in peak oxygen uptake (VO(2))...
- Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery diseaseJennifer L Robbins
Department of Medicine, Division of Cardiology, Duke University Medical Center, Box 3126, Durham, NC 27710, USA
J Appl Physiol (1985) 111:81-6. 2011..These findings suggest that alterations in microcirculation may contribute to functional impairment capacity in PAD...
- Peripheral arterial disease rehabilitation: a reviewRita A Falcone
Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
J Cardiopulm Rehabil 23:170-5. 2003
- Assessment of functional status and quality of life in claudicationRyan J Mays
Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO 80045, USA
J Vasc Surg 53:1410-21. 2011..Although this is an important measure, it does not provide information about how patients perceive the effects of their treatments on more global measures of health-related quality of life (HRQOL)...
- L-Carnitine plus cilostazol versus cilostazol alone for the treatment of claudication in patients with peripheral artery disease: a multicenter, randomized, double-blind, placebo-controlled trialNeil A Goldenberg
Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, CO 80045, USA
Vasc Med 17:145-54. 2012..145 for cilostazol/placebo (p = 0.048). QOL measures were also improved in the cilostazol/l-carnitine group. These findings support larger trials of l-carnitine in combination with cilostazol in the treatment of IC...
- A randomized trial of iloprost in patients with intermittent claudicationMark A Creager
Department of Medicine, Division of Cardiology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Vasc Med 13:5-13. 2008..039). Neither iloprost nor pentoxifylline enhanced quality of life. These results indicate that oral iloprost is not effective in improving exercise performance or quality of life in patients with PAD who have intermittent claudication...
- Increased levels of apoptosis in gastrocnemius skeletal muscle in patients with peripheral arterial diseaseRobert G Mitchell
Division of Cardiology, Department of Medicine, Durham VA and Duke University Medical Center, Durham, NC 27710, USA
Vasc Med 12:285-90. 2007..53% +/- 0.96; p < 0.001). In conclusion, PAD is associated with increased levels of apoptosis in the peripheral skeletal muscle. Further study is required to ascertain whether apoptosis plays a role in decreased functional capacity...
- Clinical outcomes using aggressive approach to anatomic screening and endovascular revascularization in a veterans affairs population with critical limb ischemiaAlap P Shah
Department of Medicine, University of Colorado Denver, Aurora, Colorado, USA
Catheter Cardiovasc Interv 74:11-9. 2009....
- Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacyWilliam R Hiatt
Department of Medicine, University of Colorado School of Medicine, Section of Vascular Medicine, and the Colorado Prevention Center, Denver, CO 80203, USA
Vasc Med 9:18-25. 2004..These data indicate that selective serotonin receptor blockade does not improve exercise tolerance or quality of life in individuals with claudication...
- Community walking programs for treatment of peripheral artery diseaseRyan J Mays
Division of Cardiology, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo Center for Women s Health Research, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, Colo Electronic address
J Vasc Surg 58:1678-87. 2013..This review evaluated the various methods and outcomes of community walking programs for PAD...
- Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trialsJeffrey S Berger
Department of Medicine, Division of Cardiology, New York University School of Medicine, New York, NY 10016, USA
Am Heart J 162:115-24.e2. 2011..The benefit of aspirin to prevent cardiovascular events in subjects without clinical cardiovascular disease relative to the increased risk of bleeding is uncertain...
- Risk assessment in the patient with established peripheral arterial diseaseScott Haugen
Divisions of Cardiology and General Internal Medicine, Department of Medicine, University of Colorado School of Medicine, Denver, CO, USA
Vasc Med 12:343-50. 2007..Defining which patients are in the highest category of risk may direct health care providers to emphasize secondary preventive measures, and facilitate patient adherence to recommended medical therapies and smoking cessation...
- Masterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudicationWilliam R Hiatt
Department of Medicine, University of Colorado School of Medicine, Section of Vascular Medicine, Divisions of Geriatrics and Cardiology, Denver, Colorado 80203, USA
Vasc Med 11:55-60. 2006..The use of aspirin as well as more potent antiplatelet therapies such as thienopyridines holds promise for reducing atherothrombosis in this very high-risk population...
- Exercise training for claudicationKerry J Stewart
Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
N Engl J Med 347:1941-51. 2002
- Improving academic leadership and oversight in large industry-sponsored clinical trials: the ARO-CRO modelNeil A Goldenberg
Department of Medicine, Section of Hematology Oncology, University of Colorado, Aurora, CO, USA
Blood 117:2089-92. 2011..Although numerous models can be entertained, the ARO-CRO model is uniquely structured to meet the demand for greater assurance of integrity in clinical trials and the needs of each stakeholder in the process...
- Patterns of artery disease in 450 patients undergoing revascularization for critical limb ischemia: implications for clinical trial designCarlos A Rueda
University of Colorado Health Sciences Center, Aurora, CO 80045, USA
J Vasc Surg 47:995-9; discussion 999-1000. 2008..The pattern and distribution of arterial occlusions and stenoses in patients with critical limb ischemia presenting at two academic medical centers was described...
- Proarrhythmic potential of dronedarone: emerging evidence from spontaneous adverse event reportingDavid P Kao
Division of Cardiology, University of Colorado School of Medicine, Aurora, Colorado, USA
Pharmacotherapy 32:767-71. 2012..To characterize the frequency and type of cardiac events, including torsade de pointes, associated with dronedarone and its structural analog, amiodarone, outside of the clinical trial setting...
- The "parallel-cohort RCT": Novel design aspects and application in the Kids-DOTT trial of pediatric venous thromboembolismNeil A Goldenberg
Dept of Pediatrics, Section of Hematology Oncology Bone Marrow Transplantation and Mountain States Regional Hemophilia and Thrombosis Center, Univ of Colorado Denver and The Children s Hospital, Aurora, CO, USA
Contemp Clin Trials 31:131-3. 2010....
- Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trialRobert W Schrier
Division of Renal Diseases and Hypertension, Department of Medicine, University of Colorado School of Medicine, Denver, CO 80262, USA
Nat Clin Pract Nephrol 3:428-38. 2007..Analysis of the results of 5 years of follow-up revealed a highly significant correlation of all-cause and cardiovascular mortality with left ventricular mass and severity of albuminuria...
- Pharmacologic therapy for peripheral arterial disease and claudicationWilliam R Hiatt
Department of Medicine, University of Colorado School of Medicine, c o Colorado Prevention Center, 789 Sherman Street, Suite 200, Denver, CO 80203, USA
J Vasc Surg 36:1283-91. 2002....